GIPR and neoplasm: Although TZP, as the first GLP‐1R/GIPR dual agonist, has been approved by the FDA for the treatment of diabetes, its anti‐tumor mechanisms and the specific relationship with receptors activation to downstream molecules still require further exploration (Figure 8).